Thursday, 17 May 2018

May Osteoporosis Drug Benefit Heart Health?

The osteoporosis drug alendronate was associated along with a reduced chance of cardiovascular death, heart attack, and stroke patients with hip fractures. The affiliation turned into visible for up to 10 years after fracture.
In this study, patients newly identified with hip fracture from 2005 thru 2013 have been observed till late 2016. Amongst 34,991 patients, 4602 (13%) acquired osteoporosis treatment throughout follow-up.

Alendronate became associated with 67% and 45% lower dangers of 1-year cardiovascular death and coronary heart attack, respectively. It was associated with an 18% decreased danger of stroke within 5 years and a 17% reduced threat of stroke inside 10 years. Defensive results have been not evident for other classes of osteoporosis treatments.
Researchers said it is properly established that there's a global-extensive crisis within the treatment of osteoporosis, because of patients' awareness of the extraordinarily uncommon side effects and their findings show that alendronate is probably cardio protective in hip fracture sufferers.
Consequently, doctors have to consider endorsing alendronate or else other nitrogen-containing bisphosphonates to hip fracture patients immediately after their fracture, as well as patients ought to additionally have appropriate compliance with alendronate treatment, as this isn't always only precise in your bones, however additionally your heart.

Further to clinical management, the study also has essential implications in clinical trial design of anti-osteoporosis medications. The USA Food and Drug management currently requested extra records earlier than attaining a selection on whether or not to approve the osteoporosis drug romosozumab, because of excess cardiovascular detrimental activities within the romosozumab arm compared with the alendronate arm. Scientists’ outcomes endorse so as that variation in cardiovascular adverse activities might be likely linked with a protective association of alendronate, as an alternative of a boom in cardiovascular adverse activities related to romosozumab use.

Friday, 4 May 2018

Reading Lengthy Descriptions? Just See How The Drug Works!

Augmented and Virtual Reality
a new view of the world through digital information

Virtual Reality (VR) is an artificial, computer-generated simulation or recreation of a actual surroundings or situation. It immerses the user by means of making them sense like they're experiencing the simulated reality first-hand, commonly by way of stimulating their imaginative and prescient and also listening.

Augmented Reality (AR) is a technology in which live vision of a natural, real-world atmosphere whose components are "augmented" by computer-generated upgrades so as to make it more prominent meaningful thru the capability to connect with it.
Augmented and virtual realities both leverage similar styles of technology. They both exist to serve the user with an enhanced or improved experience.

Augmented reality and virtual reality with devices including digital contact lens which provides us a new view of the world thru digital information. Patients can see how the drug works in 3D in front of their eyes rather than just reading lengthy descriptions. Lab technicians can monitor their experiments with augmented reality system. In Industries, employees could start working without hands on training as the tool might inform them what to do and also the way to do.

Gulf Congress on Pharmacy and Pharmaceutical Sciences going to be held on September 17-18, 2018 at Abu Dhabi, UAE goes with the theme Global Innovations & Recent Advancements in Pharmaceutical Science. Pharma Conference 2018 will be a global event focusing on the core knowledge as well as major advances in the ever-expanding field of Pharmacy and Pharmaceutical Sciences by pulling in specialists on a international level. It is a international platform to discuss the innovative researches and advancements in the Pharmaceutical field. It will be a brilliant chance to meet up renowned identities in the fields of pharmaceutics to learn the latest innovative advancements.

For more details email Catherine Jones @

Friday, 27 April 2018

Can Bacteria Produce Drugs to Treat Diseases?

Bacteria can be programmed to produce drugs efficiently

Researchers found a new approach to manage the distribution of essential resources in modified cells by advancing the capacity of synthetically programming cells to fight against disease and bring novel drugs.
They discovered a new method to control ribosomes distribution; Microscopic 'factories'-which build proteins inside the cell to maintain the cell alive and functional for both synthetic circuit and host cell.

To improve the cell, Synthetic circuitry might be included to perform specially made functions which offer the new promise for future healthcare also pharmaceuticals sciences.
A cell has only limited amount of ribosomes, the host cell where the circuitry is inserted and the synthetic circuit will compete for this limited pool of resources. To survive, multiply and thrive it is necessary to provide enough ribosomes for both or else the circuit will fail or the cell will die.
The researchers have developed and demonstrated a unique system using the engineering principal of a feedback control loop system through which ribosomes can be distributed dynamically so that more ribosomes will be allocated to synthetic circuit for proper function and less will be allocated for the host cell.
Ribosomes live inside cells, and assemble proteins whilst required for a cellular function. When a cell requires protein, the nucleus creates mRNA also sent that to the ribosomes. Later it synthesise the essential proteins via bonding the appropriate amino acids together in a chain.
To know more about Pharmaceutical Sciences visit:

Gulf Congress on Pharmacy and Pharmaceutical Sciences scheduled on September 17-18, 2018 Abu Dhabi, UAE is a international stage to talk about the innovative researches and advancements in the Pharmaceutical field. It will be a brilliant chance to meet renowned personalities in the fields of pharmaceutics and to gain knowledge of the most recent innovative advancements.

Friday, 13 April 2018

Can Diabetes Drug Suppress Nicotine Withdrawal?

Cigarette smoking harms almost every organ of the body, causes several diseases, also reduces the health of smokers in general There are three medicines authorized via the united states food and Drug administration to assist individuals break addictions to nicotine
Yet, smoking cessation rates remain low—at about 15 percent— however certain studies reveal up to 70 percent of smokers need to quit.
The three treatments currently available are nicotine replacement, an antidepressant, and then medication meant to reduce the cravings for and satisfying effects of cigarettes. Nothing exactly treats nicotine withdrawal symptoms.

The past research found that the influence of nicotine with brain chemistry. Researchers hypothesized that metformin might reduce anxiety, peevishness, also other withdrawal symptoms.
The researchers focused on activating AMP-activated protein kinase which stimulates the breakdown of glucose for energy. They set out to discover whether AMPK, stimulated through metformin, may reduce or even eliminate the symptoms of nicotine withdrawal.
Metformin suppresses liver glucose production. The researchers found that nicotine-treated mice given metformin displayed none of the anxiety or other negative effects of withdrawal. Metformin, completely prevented anxious behaviors caused by nicotine withdrawal with no side effects.
Gulf Congress on Pharmacy and Pharmaceutical Sciences is a global platform to discuss the innovative researches and developments in the Pharmaceutical field. It will be a golden opportunity to meet eminent personalities in the fields of pharmaceutics and to learn the latest technological advancements.
To know more about Pharma Conference 2018 visit:

Friday, 6 April 2018

Combining two exiting drug can prevent lung cancer?

An exciting recent research is suggesting that a novel treatment combining two currently existing and approved drugs might effectively target almost 85 percent of present lung cancers. With less side effects than traditional chemotherapy, the novel treatment is set to go into a phase 2 human clinical trial within 12 months.
Current work has been done to reveal the role of epidermal growth factor receptor (EGFR) in lung cancers. Novel drugs which inhibit EGFR have been developed, also approved for use, to treat non-small cell lung cancers (NSCLCs) but they have frustratingly shown limited efficacy, often only working 10 to 15 percent of the time.

There has been a huge attempt during the last several years to block EGFR as a treatment for lung cancer; however this treatment simply works in a minor subset of patients. The cancer fights back through a bypass pathway.
Tracking along also blocking that "bypass pathway" has been important to the novel research. The researchers found that as EGFR is blocked, levels of another protein called Tumor Necrosis Factor (TNF) rise. Consequently it appeared reasonable to explore whether EGFR inhibitors would be further efficient in treating lung cancer when combined with TNF inhibitors.
During an animal study the researchers observed that non-small cell lung cancers had been much more sensitive to EGFR inhibitors as TNF was blocked. In these early tests the researchers utilized a drug called thalidomide because the primary TNF inhibitor. As thalidomide certainly has a controversial history, it has recently been experiencing novel evaluation as a effective anti-cancer agent.

As both drugs are as of now approved for human use by the FDA it is trusted a phase 2 human clinical trial of the novel dual-drug treatment can take place fast-tracked. The future clinical trial will not only include lung cancer patients but also persons with glioblastomas, another cancer known to be linked with EGFR.
Non-small cell lung cancers comprise approximately 85 percent of all lung cancers, making this novel discovery. If established effective in human trials, this novel combination of pre-existing drugs would basically modify how lung cancers are treated.
To know more about innovative researchers in Pharmaceutical field participate at Gulf Congress on Pharmacy and Pharmaceutical Sciences

Saturday, 31 March 2018

Can Dietary supplement reverse cardiovascular aging?

A novel nutraceutical known as nicotinomide riboside has been observed to kick-start the identical biological pathways as calorie limit does, and improve arterial health in people with moderate hypertension.
Scientists have long recognized that limiting calories can fend off physiological symptoms of aging, with research in fruit flies, roundworms, rodents and even humans showing that chronically slashing consumption by using approximately a third can attain myriad health benefits and, in some instances, extend lifespan

A Study says when people consume a herbal nutritional supplement known as nicotinomide riboside (NR) day by day, it mimics caloric restriction, aka "CR," kick-starting the identical key chemical pathways liable for its health benefits.
Supplementation additionally tends to enhance blood pressure and arterial health, especially in people with mild hypertension, the study found.
The researchers took blood samples as well as various physiological estimations at the end of every treatment.
Individuals (Participants) reported no extreme adverse effects.
The researchers observed that 1,000 mg each day of NR boosted levels of every other compound known as nicotinamide adenine dinucleotide (NAD+) by means of 60 percentage. NAD+ is needed for activation of enzymes referred to as sirtuins, which are largely credited with the useful results of calorie limit. It is involved in a number of metabolic actions all through the body, however it tends to decline with age.

Studies indicate that as an evolutionary survival mechanism, the body conserves NAD+ when subjected to calorie limit. However only these days have scientists began to discover the concept of supplementing with so-known as "NAD+-precursors" like NR to promote healthy aging.
The new study additionally observed that in 13 individuals with increased blood pressure or stage 1 hypertension (120-139/80-89 mmHg), systolic blood pressure was approximately 10 points decreased after supplementation. A drop of that magnitude ought to translate to a 25 percentage reduction in heart attack risk.
Ultimately, CR-mimicking compounds may want to provide a further option alongside the nutritional modifications and exercise currently recommended for people whose blood pressure is not yet excessive enough to warrant medicinal drug however who are still at danger for a heart attack.

Friday, 23 March 2018

Can Diabetes Drug Help People with Obesity?

A compound that mimics a naturally occurring hormone that regulates appetite might also assist humans who've obesity however not diabetes to lose weighta new study indicates.

The compound, semaglutide, has a chemical structure that is very similar to the hormone glucagon-like peptide 1 (GLP-1), which regulates both insulin secretion and appetite.

Researchers says "This randomized study of weight reduction triggered with semaglutide in humans with weight problems however without diabetes has proven the very best weight reductions but seen for any pharmaceutical intervention”.

The new study included 957 individuals, 35 percent of whom were male. All individuals had a body mass index (BMI) of as a minimum 30, however did not have diabetes. They have been randomly assigned to seven specific groups5 groups acquired specific doses of semaglutide (between 0.05 mg and zero.4 mg) via injection as soon as each day; a 6th group received a placebo, and a 7th group acquired 3 mg of the diabetes drug liraglutide. All individuals acquired month-to-month weight loss plan and workout counselling.

After one year, all individuals receiving semaglutide had lost drastically more weight than the ones receiving placebo. The higher the dose individuals acquired, the extra their average weight lossindividuals who obtained0.05 mg of semaglutide daily lost a mean of 6.0 percentage of their body weight; the 0.1 mg group lost a medianof 8.6 percentage; the 0.3 mg group lost a mean of 11.2 percentageand people receiving a every day dose of 0.4mg lost a mean of 13.8 percentthe ones receiving liraglutide lost a mean of 7.eight percent of their bodyweight, at the same time those in the placebo group lost only 2.3 percent on common.

Sixty five percent of individuals who obtained 0.4 mg of semaglutide per day lost as a minimum 10 percent in their body weight, as compared with 10 percentages of these within the placebo group and 34 percentage of the liraglutide group.

The most not unusual adverse occasions in those taking semaglutide have been slight/mild nausea, as seenformerly with GLP-1 receptor agonists.

Researchers cited that similarly researches of semaglutide for obesity are underway.

To know more about what is happening in Pharmaceutical field visit